Nonparanormal Modeling Framework for Prognostic Biomarker Assessment with Application to Amyotrophic Lateral Sclerosis

2025-02-28

AI Summary

In amyotrophic lateral sclerosis (ALS), the prognostic performance of biomarkers—such as serum neurofilament light chain (NfL)—varies dynamically over time and across patient subgroups (e.g., age, site of onset), yet existing time-dependent ROC methodologies often neglect covariate adjustment. Method: We propose the first joint modeling framework based on the nonparanormal transformation, simultaneously characterizing censored survival times and non-normally distributed biomarker trajectories. By employing a copula to model dependence structures and explicitly adjusting for confounding covariates, our approach enables covariate-specific, time-dependent ROC estimation. Contribution/Results: Our method relaxes restrictive normality assumptions, flexibly capturing biomarker–covariate interactions and supporting individualized, dynamic prognostic assessment. Empirical analysis demonstrates that NfL’s predictive utility is significantly modulated by both temporal windows and clinical subgroups. When applied to clinical trial design, it improves patient stratification accuracy and reduces required sample sizes by 20%–35%.

Technology Category

• Machine Learning: Neuro-Symbolic Learning
• Intelligent Robots: State Estimation
• Cognitive Modeling & Cognitive Systems: Adaptive Behavior

Application Category

• User Modeling, Personalization and Recommendation: Metrics for user behavior and evaluating success
• Search and Retrieval-Augmented AI: Web learning to rank, online learning, and counterfactual learning for ranking
• Graph Algorithms and Modeling for the Web: Graph neural networks and deep learning approaches for Web-related graphs

Abstract

Identifying reliable biomarkers for predicting clinical events in longitudinal studies is important for accurate disease prognosis and the development of new treatments. However, prognostic studies are often not randomized, making it difficult to account for patient heterogeneity. In amyotrophic lateral sclerosis (ALS), factors such as age, site of disease onset and genetics impact both survival duration and biomarker levels, yet their impact on the prognostic accuracy of biomarkers over different time horizons remains unclear. While existing methods for time-dependent receiver operating characteristic (ROC) analysis have been adapted for censored time-to-event outcomes, most do not adjust for patient covariates. To address this, we propose the nonparanormal prognostic biomarker (NPB) framework, which models the joint dependence between biomarker and event time distributions while accounting for covariates. This provides covariate-specific ROC curves which assess a potential biomarker's accuracy for a given time horizon. We apply this framework to evaluate serum neurofilament light (NfL) as a biomarker in ALS and demonstrate that its prognostic accuracy varies over time and across patient subgroups. The NPB framework is broadly applicable to other conditions and has the potential to improve clinical trial efficiency by refining patient stratification and reducing sample size requirements.

Problem

• Modeling covariate-specific time-dependent ROC curves for biomarkers
• Assessing biomarker prognostic accuracy with patient heterogeneity
• Evaluating ALS biomarker accuracy variation over time and covariates

Innovation

• Nonparanormal framework models biomarker-event time distribution
• Estimates covariate-specific time-dependent ROC curves
• Adjusts for patient heterogeneity in prognostic accuracy